Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 179

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 179
---
. dollars, except share and per share data) 

    Year Ended December 31,

    2024

    2023

    Revenue:

    Collaboration agreements
     
    $
    53,477

    $
    51,133

    Operating expenses:

    Research and development, net of tax credits

    115,941

    133,593

    General and administrative

    29,680

    33,764

    Restructuring

    1,379

    —

    Total operating expenses

    147,000

    167,357

    Loss from operations

    (93,523
    )

    (116,224
    )

    Other income (expense), net

    Realized and unrealized loss on foreign exchange

    (2
    )

    (170
    )

    Interest income

    10,391

    13,334

    Other expense, net

    (115
    )

    (119
    )

    Total other income, net

    10,274

    13,045

    Loss before income taxes

    (83,249
    )

    (103,179
    )

    Income tax (expense) benefit

    (1,440
    )

    9,383

    Net loss
     
    $
    (84,689
    )
     
    $
    (93,796
    )

    Other comprehensive income:

    Unrealized gain on available-for-sale marketable securities

    26

    456

    Total other comprehensive income
     
    $
    26

    $
    456

    Comprehensive loss
     
    $
    (84,663
    )
     
    $
    (93,340
    )

    Net loss per share attributable to common shareholders—basic and diluted
     
    $
    (2.00
    )
     
    $
    (2.23
    )

    Weighted-average common shares outstanding—basic and diluted

    42,411,085

    42,093,293

The accompanying notes are an integral part of these consolidated financial statements 

103

Repare Therapeutics Inc.

Consolidated Statements of Shareholders’ Equity 

(In thousands of U.S. dollars, except share data) 

    Common Shares

    Warrants

    Additional

    Accumulated Other Comprehensive

    Accumulated

    Total Shareholders'